CagriSema: Will the New Duo Outperform Mounjaro and Ozempic

Imagine you're already taking Ozempic and getting decent results. Now add another hormone that enhances satiety through a completely different mechanism. This is exactly the idea Novo Nordisk has implemented in their new product. CagriSema is not just an updated version of Ozempic. It's a fundamentally new approach that combines two hormones in one injection.

The results are impressive: 22.7% weight loss over 68 weeks [4]. But there's a catch. In a head-to-head comparison with Mounjaro, CagriSema lost. And this changes the entire landscape of weight loss medications.

Short answer: CagriSema is effective, but Mounjaro remains the leader

CagriSema is a combination of semaglutide 2.4 mg and cagrilintide 2.4 mg in one weekly injection. It demonstrated 22.7% weight loss over 68 weeks in the REDEFINE 1 trial, 40% better than semaglutide alone (16.1%). Cagrilintide—an amylin analogue—activates different satiety receptors than GLP-1, creating a dual effect on appetite.

However, in the head-to-head REDEFINE 4 trial, Mounjaro (tirzepatide 15 mg) showed 25.5% weight loss versus 23% on CagriSema over 84 weeks. CagriSema missed the non-inferiority endpoint, meaning Mounjaro is statistically more effective. Both drugs deliver clinically significant results above 20%, but tirzepatide remains the most potent approved weight-loss medication today. CagriSema awaits FDA decision in late 2026.

What is CagriSema in Simple Terms

CagriSema is a combination of two active ingredients in one injection. The first component is semaglutide 2.4 mg, the same as in Ozempic and Wegovy. The second component is cagrilintide 2.4 mg, an analog of the hormone amylin [2].

It is administered once weekly subcutaneously. The mechanism is simple: two different hormones act on different receptors in the brain, creating a more powerful satiety effect than either one alone.

As of today, CagriSema has not yet received FDA approval. The company submitted an application in December 2025, with a decision expected by late 2026 [2]. In Ukraine, the product is not yet officially available.

Amylin and Cagrilintide: The Second Satiety Hormone Missing from Ozempic

Amylin is a natural hormone produced by the pancreas along with insulin after eating. In people with excess weight, amylin signals are often weakened. The brain doesn't receive a clear message that there's been enough food [16].

Cagrilintide is a long-acting synthetic analog of amylin. It activates amylin receptors (AMY1, AMY2, AMY3) in brain regions responsible for appetite and satiety [20]. It's important to understand: these receptors are completely different from the GLP-1 receptors that semaglutide targets.

Studies in rats revealed an interesting detail. CagriSema doesn't just reduce food intake. It also preserves the body's energy expenditure [35]. Typically, metabolism slows down during weight loss—it's the body's protective response. The combination of semaglutide with amylin partially blocks this adaptation.

Approximately one-third of weight loss on CagriSema is explained by its effect on energy expenditure, not just appetite reduction. This may explain why the combination of two hormones delivers better results than either one alone.

How CagriSema Combines Semaglutide and Amylin — The Dual Action Mechanism

Semaglutide and cagrilintide work through different biological pathways. Semaglutide activates GLP-1 receptors, reducing appetite, slowing gastric emptying, and stabilizing blood sugar levels. Cagrilintide activates amylin receptors, enhancing satiety through the area postrema and nucleus tractus solitarius in the brainstem [20].

An early 2021 study showed that this combination truly works additively. In 95 participants with excess weight, adding cagrilintide to semaglutide 2.4 mg over 20 weeks resulted in 15.7-17.1% weight loss compared to 9.8% on semaglutide alone [32].

CagriSema's mechanism of action is fundamentally different from Mounjaro. Tirzepatide in Mounjaro activates two incretin receptors: GLP-1 and GIP. CagriSema combines a GLP-1 agonist with an amylin analog. Different targets, different pathways [20].

REDEFINE and REIMAGINE Results — How Many Kilograms Are Lost

CagriSema's clinical trial program includes two main series: REDEFINE for weight loss and REIMAGINE for type 2 diabetes.

REDEFINE 1: The Main Efficacy Study

The study enrolled 3,417 adults with obesity or overweight and at least one comorbidity, without type 2 diabetes [2]. The average baseline weight was 106.9 kg.

Comparison results:

• CagriSema: -22.7%
• Semaglutide 2.4 mg alone: -16.1%
• Cagrilintide 2.4 mg alone: -11.8%
• Placebo: -2.3% [4]

An important nuance: only 57.3% of participants in the CagriSema group reached the maximum dose. For comparison, 70.2% of participants on semaglutide alone received the maximum dose [4]. This means CagriSema's true potential may be even higher.

REDEFINE 2: Patients with Type 2 Diabetes

REDEFINE 2 enrolled 1,206 adults with overweight and type 2 diabetes. CagriSema showed 15.7% weight loss compared to 3.1% on placebo over 68 weeks [2]. Additionally, 89.7% of participants on CagriSema lost at least 5% of their weight versus 30.3% on placebo.

The REIMAGINE Program for Diabetes

Three REIMAGINE 1-3 studies demonstrated CagriSema's efficacy in glycemic control and weight reduction in patients with type 2 diabetes [1].

REIMAGINE 1 (189 participants with diabetes uncontrolled by lifestyle alone): HbA1c reduction of 1.8 percentage points and 13.8% weight loss on CagriSema versus 0.1% and 1.4% on placebo, respectively [5].

REIMAGINE 2 (2,713 participants on metformin): CagriSema outperformed semaglutide in both HbA1c reduction and weight loss [8]. HbA1c reduction was 2.02% on CagriSema versus 1.88% on semaglutide 2.4 mg; weight loss was 14.2% versus 10.2% [25].

CagriSema vs Mounjaro: What the Head-to-Head Comparison Showed

Here's where things get interesting. REDEFINE 4 is the first and only head-to-head comparison of CagriSema with tirzepatide (Mounjaro). Results were announced in February 2026 [6].

CagriSema did not meet the study's primary endpoint—non-inferiority compared to tirzepatide [10]. Simply put, Mounjaro proved more effective.

The study enrolled 809 participants with an average baseline weight of 114 kg [10]. CagriSema showed 23% weight loss with treatment adherence; tirzepatide showed 25.5%. The difference may seem small, but it is statistically significant.

This result was a serious blow for Novo Nordisk. The company's shares fell after the results were announced [22]. But context matters: both medications show clinically significant weight loss exceeding 20%. For many people, this can be life-changing.

CagriSema vs Ozempic: What's the Difference

When comparing CagriSema to Ozempic alone, the picture is completely different. In REDEFINE 1, CagriSema outperformed semaglutide 2.4 mg by 6.6 percentage points in weight loss: 22.7% versus 16.1% [3].

It's important to note: in REDEFINE 1, semaglutide was used at the 2.4 mg dose found in Wegovy for weight loss. Standard Ozempic for diabetes contains a maximum of 1 mg semaglutide.

In the REIMAGINE program for diabetes, CagriSema also outperformed semaglutide. In REIMAGINE 2, weight loss was 14.2% on CagriSema versus 10.2% on semaglutide 2.4 mg [25]. Additionally, 43% of participants on CagriSema achieved ≥15% weight loss, compared to a smaller proportion on semaglutide.

CagriSema showed better glycemic control: HbA1c reduction of 2.11% versus 1.93% on semaglutide [12]. No weight plateau was observed through the end of the 68-week study, suggesting potential for further weight loss [25].

CagriSema Side Effects and Tolerability

CagriSema's safety profile is consistent with the GLP-1 agonist class, but with a higher frequency of gastrointestinal symptoms due to its dual mechanism.

Nausea is the most common side effect, occurring in more than half of participants [7]. This is significantly higher than on semaglutide alone. However, important details:

• Most symptoms were classified as mild to moderate [17]
• Symptoms decreased over time
• Treatment discontinuation due to side effects was only 6% on CagriSema versus 3.7% on placebo [17]

In REDEFINE 2 (patients with diabetes), gastrointestinal events occurred in 72.5% of participants on CagriSema [27]. Discontinuation due to side effects was 8.4% versus 3% on placebo [17].

When Will CagriSema Be Available and What to Do Now

Novo Nordisk submitted CagriSema for FDA approval in December 2025 [18]. A decision is expected by late 2026. Applications to European regulators or MHRA (United Kingdom) have not been publicly confirmed [3].

For Ukraine, this means CagriSema won't appear before 2027-2028, even under an optimistic scenario.

What's Available Right Now?

Good news: a separate component of CagriSema—Amylin (Cagrilintide)—is already available at DOZA.

The key difference: Amylin acts through amylin receptors, which do not overlap with GLP-1 or GIP receptors. Therefore, it can be added to Mounjaro, Ozempic, or other GLP-1 products for a synergistic effect [20].

If you're already on a Mounjaro program and want to enhance your results without increasing the dose—amylin may be an option. But this decision should be made together with a specialist after evaluating your individual situation.

Three Approaches to Dual Action: How the Mechanisms Compare

Three main strategies for combination weight loss therapy are currently emerging on the market:

1. GLP-1 + GIP (Mounjaro/Tirzepatide)

Two incretin hormones act synergistically on glucose metabolism and appetite. Result: up to 25.5% weight loss over 84 weeks [6]. Learn more about Mounjaro's mechanism.

2. GLP-1 + Amylin (CagriSema)

Incretin plus amylin—different appetite regulation systems. Result: up to 22.7% weight loss over 68 weeks [4].

3. GLP-1 + GIP + Glucagon (Retatrutide)

The triple agonist shows the best results of all: up to 28.3% over 80 weeks in Phase 3 TRIUMPH-1 (topline 2026); Phase 2: 24.2% over 48 weeks [42]. But it's still in clinical trials.

Read also: Three Weight Loss Mechanisms: Amylin vs Mounjaro vs Ozempic.

What These Results Mean for Your Choice

CagriSema is a significant step forward compared to Ozempic. Adding amylin increases semaglutide's efficacy by 40% (from 16.1% to 22.7% weight loss). For those not getting sufficient results on GLP-1 agonists alone, this could be a solution.

But the head-to-head comparison with Mounjaro showed: tirzepatide remains the most effective available medication. The dual incretin strategy (GLP-1 + GIP) proved superior to the GLP-1 + amylin combination.

CagriSema won't appear before 2027. Until then, the combination of Mounjaro + Amylin may deliver comparable results. But this decision should be discussed with a DOZA specialist who can evaluate your situation individually.